Search clinical trials for: Siltuximab

Total 2238 results

Tianjin Medical University Cancer Institute and...

Recruiting

A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
Northwestern University
Robert H. Lurie Cancer Center

Terminated

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

Lymphoma

United States
University College, London
Cancer Research UK

Completed

Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma (MCLPIII)

Lymphoma

United Kingdom, Australia
National Institute of Diabetes and Digestive and...
Genentech, Inc.; Indiana University

Completed

Rituximab Treatment of Focal Segmental Glomerulosclerosis

Focal Segmental Glomerulosclerosis (FSGS)

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Withdrawn

Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia

United States
Chinese University of Hong Kong

Completed

An Analysis of Peripheral Blood T Cell Subsets on Rheumatoid Arthritis

Rheumatoid Arthritis

China
Peng Liu

Recruiting

Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma

Diffuse Large B Cell Lymphoma

China
University of California, San Diego

Active, not recruiting

Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

United States
Memorial Sloan Kettering Cancer Center

Completed

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

Lymphoma | Mantle Cell Lymphoma

United States
Incyte Corporation

Withdrawn

A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma (CITADEL-310)

Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Lymphoma

United States
Bayer

Completed

Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia

Leukemia

United States
King Faisal Specialist Hospital & Research Center
Society of Critical Care Medicine

Unknown

Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19

Critical Illness | Corona Virus Infection | Cytokine Release Syndrome

Saudi Arabia
Huiqiang Huang

Recruiting

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | EBV-Positive DLBCL, Nos | ALK-Positive Anaplastic Large Cell Lymphoma | Follicular Lymphoma Grade IIIb

China
Aptevo Therapeutics

Terminated

Phase 1b Safety and Efficacy Study of TRU-016

Chronic Lymphocytic Leukemia | Peripheral T-cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH

Completed

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy (PTLD-2)

Posttransplant Lymphoproliferative Disorder

Germany
The First Affiliated Hospital of Soochow University

Recruiting

Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell Lymphoma

Untreated Mantle Cell Lymphoma

China
National Health Research Institutes, Taiwan
China Medical University Hospital; Chang Gung Memorial Hospital; Taipei Veterans... and other collaborators

Not yet recruiting

A Phase I/II Study of Diffuse Large B-cell Lymphoma (DLBL)

Refractory Diffuse Large B-cell Lymphoma
Assistance Publique - Hôpitaux de Paris
French Vasculitis Study Group

Completed

Rituximab in Eosinophilic Granulomatosis With Polyangiitis (REOVAS)

Eosinophilic Granulomatosis With Polyangiitis (EGPA)

France
National Cancer Institute (NCI)

Terminated

Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone... and other conditions

United States
Hoffmann-La Roche

Completed

GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Belgium, Italy, Spain, United States, Canada, Sweden, Greece, Netherlands, Austria, Switzerland, Poland, Turkey, Croatia, Brazil, Argentina, Denmark, United Kingdom
Auxilio Mutuo Cancer Center

Completed

Phase II Evaluation of Gemcitabine- Rituximab-Oxaliplatin Combination (GROC) in Relapsed Aggressive Lymphomas

Refractory Aggressive Non-Hodgkin's Lymphoma | Relapsing Aggressive Non-Hodgkin's Lymphoma
Asociacion Espanola de Hematologia y Hemoterapia

Completed

Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma

Non Hodgkin Lymphoma

Spain
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM (ZBR)

Waldenstrom Macroglobulinemia

China
MorphoSys AG
ICON Clinical Research

Active, not recruiting

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (B-MIND)

Diffuse Large B-cell Lymphoma

United States, Hungary, Italy, Poland, Spain, Czechia, Germany, Australia, Austria, Canada, Croatia, Finland, France, Israel, Korea, Republic of, New Zealand, Portugal, Romania, Serbia, Singapore, Taiwan, Turkey, United Kingdom
Mayo Clinic
Columbia University; Genentech, Inc.; Stanford University; Ohio State University; Bioge... and other collaborators

Completed

Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy

IgA Nephropathy

United States
Assiut University

Unknown

Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children

Refractory Epilepsy
Ohio State University Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade... and other conditions

United States
Hoffmann-La Roche

Completed

CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy

Lymphocytic Leukemia, Chronic

Austria
Sanofi

Terminated

A Study of Isatuximab-based Therapy in Participants With Lymphoma

Lymphoma

Korea, Republic of, Portugal, France, Taiwan, Italy, Netherlands, Spain
Sanofi

Terminated

Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Prostate Cancer | Non-small Cell Lung Cancer

Taiwan, United States, France, Italy, United Kingdom
Genmab
AbbVie

Recruiting

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, United Kingdom, Belgium, Denmark, Netherlands, Finland, Czechia, Sweden, Australia, Norway
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma | CCND1 Positive | CD20-Positive Neoplastic Cells Present
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
Yazeed Sawalha

Recruiting

Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

United States
Emory University
National Cancer Institute (NCI); Novartis; National Institutes of Health (NIH); EUSA Pharma, Inc...

Completed

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Qingdao Central Hospital

Recruiting

Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial

Overall Survival

China
University of California, Davis

Not yet recruiting

Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid

Bullous Pemphigoid

United States
National Institute of Diabetes and Digestive and...
National Institutes of Health (NIH)

Recruiting

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes (TN25)

Type 1 Diabetes Mellitus

United States, Australia
Scripps Health

Withdrawn

Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Hoffmann-La Roche
Genentech, Inc.; German CLL Study Group

Completed

CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)

Lymphocytic Leukemia, Chronic

Australia, France, Germany, Italy, Spain, Hong Kong, Canada, Switzerland, Estonia, Mexico, New Zealand, Denmark, Russian Federation, United States, Austria, Bulgaria, Czechia, United Kingdom, Thailand, Romania, Croatia, Brazil, Arge... and more
Providence Health & Services

Terminated

Multi-Drug Desensitization Protocol for Heart Transplant Candidates

Heart Transplantation

United States
NYU Langone Health

Not yet recruiting

Isatuximab in Lung Transplant Recipients

Antibody-mediated Rejection | Allosensitization

United States
Tufts Medical Center
Sanofi

Withdrawn

Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis

Amyloidosis | Light Chain (AL) Amyloidosis
Sun Yat-sen University

Recruiting

A Phase II Study of Rituximab, Chidamide, Zanubrutinib-induced and CHOP Therapy

Double Express Diffuse Large B-cell Lymphoma

China
Prof. Dr. M. Dreyling (co-chairman)
LMU Klinikum

Recruiting

ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Mantle Cell Lymphoma

Germany, Sweden, Denmark, Italy, Norway
BeiGene

Active, not recruiting

Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Japan
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE

Systemic Lupus Erythematosus

United States, Russian Federation, France, Spain, Korea, Republic of, Germany, Brazil, Netherlands, Canada, Mexico, Argentina
Istituto Giannina Gaslini
Bambino Gesù Hospital and Research Institute

Terminated

Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome

Nephrotic Syndrome Steroid-Dependent

Italy

Search clinical trials for: Siltuximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations